Urinary Stress Incontinence Clinical Trial
— MUSICOfficial title:
Open-label, Monocentric, First-in-man Trial to Assess Safety and Tolerability of a New Therapeutic Strategy for Stress Urinary Incontinence Based on the Implantation of Muscle Precursor Cells (MPCs)
Verified date | October 2021 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The rising success of cell therapies places an increasing burden on health care costs. Consequently, the need to reduce production costs while maintaining quality has been widely acknowledged. In addition, the demand for high-quality products with an optimal safety profile is increasing. The proposed cell treatment is the first therapeutical option with the possibility to revert the underlying condition. The investigators expect that this healing response will be achieved with minimal side effects justifying the addional costs and complexity.
Status | Completed |
Enrollment | 10 |
Est. completion date | October 21, 2021 |
Est. primary completion date | September 3, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 60 Years |
Eligibility | Inclusion Criteria: Adult women 20y-60y - Incontinence >/= grade I since at least 6 months - Predominant clinical diagnosis of SUI - Candidate for a surgical treatment (artificial urinary sphincter, synthetic compressive tapes or adjustable balloons). - Post void residual volume of <100 ml (exclusion of overflow incontinence) - Can independently use toilet without difficulty - Capacity to answer the questionnaires of evaluation - Negative blood test for: Human immunodeficiency virus (HIV 1/2), Hepatitis B HBsAg, Anti HBc, Hepatitis C Anti-HCV-Ab, Syphilis - Competent to comprehend, sign and date informed consent form before any study-specific procedure is performed Exclusion Criteria: - History of anti-incontinence or prolapse surgery. - Previous diagnosis of any of the following conditions, disorders, or diseases of the urinary tract: - Clinically significant cystocele or rectocele - Ureteric bladder, urethral or rectal fistula - Uncorrected congenital abnormality leading to urinary incontinence - Interstitial cystitis - Urinary urgency that results in leakage (as a predominant symptom) - Adult enuresis - Urodynamically proven detrusor instability - Sensory urgency defined as first sensation of bladder fill (urge to void) of <100 ml; bladder capacity of <300 ml - No sensation at any time during the simple filling cystometry procedure - Known urethral stenosis (ureterocystoscopy) or urethral diverticulum - History of urogenital cancer or history of pelvic radiotherapy - Women who are pregnant, breast feeding or <12 months postpartum Note: Female subjects who are surgically sterilized, hysterectomized or post-menopausal for longer than 2 years are not considered as having child bearing potential. No pregnancy test will be performed for this population. - Untreated symptomatic urinary tract infection - Fever (as defined by = 38,5°C, axillar measurement), any infectious disease, cold or flu within the last 7 days - Unstable severe systemic disease including uncontrolled hypertension, unstable angina, or myocardial infarction, severe coagulation disorders, bleeding diathesis, emboli, thrombophlebitis, infectious diseases, poor wound healing, and poorly controlled diabetes mellitus within 6 months before enrolment - Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results. - Known allergy or intolerance of at least one of the active ingredients or excipients of the investigational products - Known allergy or intolerance of Penicillin or Streptomycin - Known genetically determined or acquired muscular disease. - Known Neurological disorder (Parkinson's disease, multiple sclerosis, spina bifida, medullary traumatism). - Medication regimen including estrogens, anti-estrogens or diuretics where dose and/or frequency has not been stable for at least the past 12 weeks or is anticipated to change during the course of the study. - Chronic use of any of the following drugs and not stopped for at least 2 weeks prior to inclusion into the study: selective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI), alpha-receptor antagonists/agonists, beta-3-receptor agonists or anticholinergic/-muscarinic drugs. - Chronic use of any of the following drugs and not stopped for at least 6 months prior to inclusion into the study: Antidepressants or neuroleptic drugs. |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Zurich | Zürich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich | Salzburger Landeskliniken, University Hospital Tuebingen |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of clinically relevant Adverse Events of MPCs or related to cell injection | Number of clinically relevant findings related to cell injection | at 3 months post-implantation | |
Secondary | Feasibility of MPC injection | Percentage of subjects with successful injection | day of implantation | |
Secondary | Efficacy of MPC injection measured by post-void residual volume | post-void residual volume | at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation | |
Secondary | Efficacy of MPC injection measured by Uroflowmetry | Uroflowmetry: urinary flow pattern | at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation | |
Secondary | Efficacy of MPC injection measured by Urodynamic Evaluation | 2 Filling-Cystometries | at baseline, 3 months and 6 months post-implantation | |
Secondary | Efficacy of MPC injection measured by Urodynamic Evaluation | 2 Pressure-Flow studies | at baseline, 3 months and 6 months post-implantation | |
Secondary | Efficacy of MPC injection measured by Urodynamic Evaluation | Urethal-Pressure-Profile | at baseline, 3 months and 6 months post-implantation | |
Secondary | Efficacy of MPC injection measured by 1h pad test | 1h pad test | at baseline, 1 month, 3 months and 6 months post-implantation | |
Secondary | Efficacy measured by average Incontinence Score | Incontinence Score. Range from 0 (no incentinence) to 21 (highly incontinent) | at baseline, 1 month, 3 months and 6 months post-implantation | |
Secondary | Efficacy measured by average score of Visual Analog Scale of degree of suffering | Visual Analog Scale of degree of suffering. Range 0 (worst) to 10 (best) | at baseline, 1 month, 3 months and 6 months post-implantation | |
Secondary | Efficacy measured by average score of Quality of Life | Quality of Life Score, using SF-36v2™ Health Survey | at baseline, 1 month, 3 months and 6 months post-implantation | |
Secondary | Efficacy | Number for (planned) subsequent incontinence surgery | 6 months post-implantation | |
Secondary | Number of patients with abnormal laboratory values and/or Adverse Events that are related to MPC injection | Safety measures (ultrasound, physical examination, laboratroy) | at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02867748 -
TVT-ABBREVO Versus SERASIS for the Treatment of Female Urinary Stress Incontinence: 1 Year Outcomes of a Comparative Study With 2 Trans-obturator Sub Mid Urethral Slings
|
N/A | |
Recruiting |
NCT02617797 -
Radiofrequency in the Female Stress Urinary Incontinence
|
N/A | |
Active, not recruiting |
NCT02538991 -
TVT Versus Bulkamid®-Injections in Treatment of Stress Urinary Incontinence
|
N/A | |
Completed |
NCT02480231 -
Mid-Urethral Sling Tensioning Trial
|
N/A | |
Terminated |
NCT02591381 -
Transcorporal Versus Standard Artificial Urinary Sphincter Placement
|
N/A | |
Completed |
NCT00984958 -
Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure
|
N/A | |
Completed |
NCT00190567 -
Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence
|
Phase 2 | |
Completed |
NCT02423486 -
The Comparison of Efficacy Between Electromagnetic Stimulation Therapy and Electromagnetic Stimulation Therapy With Extracorporeal Biofeedback
|
N/A | |
Completed |
NCT01754558 -
One Year Outcome Using the Ajust System for Treatment of Urinary Stress Incontinence
|
N/A | |
Recruiting |
NCT00136071 -
Transvaginal Tension Free Vaginal Tape-Obturator (TVT-O) Versus Transobturator Tape-Mentor (TOT) in the Management of Urodynamic Stress Urinary Incontinence
|
N/A | |
Completed |
NCT00190619 -
Efficacy and Safety of Duloxetine
|
Phase 3 | |
Completed |
NCT04288648 -
Pelvic Floor Contraction in Different Positions Among Women With and Without Stress Urinary Incontinence
|
||
Active, not recruiting |
NCT05182632 -
Tele-rehabilitation Group Program for Urinary Incontinence in Older Women
|
N/A | |
Completed |
NCT03672461 -
A Group-Based Therapeutic Yoga Intervention for Urinary Incontinence in Ambulatory Older Women
|
N/A | |
Completed |
NCT02407145 -
Safety and Efficacy of PVDF (DynaMesh®-SIS Soft) Retropubic Midurethral Slings in Stress Urinary Incontinence in Women
|
||
Completed |
NCT01784172 -
Efficacy and Safety Study of Electroacupuncture for Simple Female Stress Urinary incontinence-a Multicenter Trial
|
Phase 2 | |
Not yet recruiting |
NCT06469320 -
Urinary Incontinence and Other Pelvic Floor Dysfunctions in Trail Runners
|
||
Recruiting |
NCT02935803 -
A Study on the Anti-incontinent Effectiveness of the mTVM Method in POPQ Stage II-III Patients
|
N/A | |
Active, not recruiting |
NCT02039830 -
Group Versus Individual Physiotherapy for Urinary Incontinence in Aging Women
|
N/A | |
Recruiting |
NCT04817839 -
Optimal Duration of Post-Operative Activity Restriction After Midurethral Sling Procedures
|
N/A |